Tin tức & Cập nhật

Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
08 Aug 2024 bởiStephen Padilla

In patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy (LOT), treatment with belantamab mafodotin (belamaf) plus pomalidomide and dexamethasone (BPD) results in statistically significant and clinically meaningful progressive-free survival (PFS) compared with pomalidomide plus bortezomib and dexamethasone (PVD), as shown in the DREAMM-8 study.

Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
08 Aug 2024
Cabozantinib and SBRT: Two feasible post-IO strategies in HCC
Cabozantinib and SBRT: Two feasible post-IO strategies in HCC
07 Aug 2024 bởiNatalia Reoutova

Liver cancer is a major cause of death globally and in Hong Kong. Both first- and second-line treatment of the disease have evolved considerably over recent years, following the approval of immune checkpoint inhibitors (ICIs). At present, over half of hepatocellular carcinoma (HCC) patients require second-line treatment, yet data on therapies administered after immunotherapy are lacking. This article summarizes locally reported findings on use of cabozantinib and stereotactic body radiotherapy (SBRT) in HCC patients who progressed on immunotherapy.

Cabozantinib and SBRT: Two feasible post-IO strategies in HCC
07 Aug 2024
Cervical cancer, leukaemia survivors face heightened risks during pregnancy
Cervical cancer, leukaemia survivors face heightened risks during pregnancy
06 Aug 2024 bởiJairia Dela Cruz

Pregnancies in women who have survived cervical cancer or leukaemia should be considered high-risk due to the potential for multiple severe obstetric complications, as reported in a study.

Cervical cancer, leukaemia survivors face heightened risks during pregnancy
06 Aug 2024
KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer
KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer
05 Aug 2024
One-time sigmoidoscopy fends off colorectal cancer risk for up to 2 decades
One-time sigmoidoscopy fends off colorectal cancer risk for up to 2 decades
02 Aug 2024 bởiJairia Dela Cruz

Once-only screening with flexible sigmoidoscopy appears to provide prolonged protection against colorectal cancer (CRC), reducing both incidence and mortality rates for up to 2 decades, according to the updated results of the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

One-time sigmoidoscopy fends off colorectal cancer risk for up to 2 decades
02 Aug 2024